FUNDING OPPORTUNITIES INFORMATIONAL WEBINAR
Watch on Demand
This webinar provides an overview of our Foundation's funding strategy, open funding opportunities,
and the application and review processes.
About the Foundation
Strategic Partnerships
Diagnosis & Symptoms
Life with Parkinson's
Navigating the System
Relationships
For Clinicians
Treatment Options
Promising New Science
Learn More, Feel Better
Donate to Find a Cure
Tribute Pages
Participate in Clinical Trials
Fundraise with Team Fox
More Ways to Get Involved
Apply for a Grant
Foundation Driven Studies
Tools & Resources
Scientific Advisors
Our Work With Industry
Sponsored Prizes
HOME › For Researchers › APPLY FOR A GRANT ›
The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease (PD) is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the advancement of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.
Target Advancement awards support research characterizing promising, novel PD-relevant targets or continuing target biology work on established PD targets. Preferred targets for this program already demonstrate links to PD in human patient populations. These awards are well-suited to projects in which hypothetical or experimental rationale for a target is compelling but limited, and study results can make the case for continuing (or discontinuing) a line of research. Full details are available in the RFA and application template below.
We will begin accepting applications for for our next funding cycle on March 11, 2019.
Projects designed to assess emerging PD targets in pre-clinical models, human cellular models and human tissue and fluid matrices are eligible for this initiative. Applicants are encouraged to leverage existing resources if possible. Studies utilizing biosamples available through MJFF-sponsored biospecimen collections or the Parkinson's Progressive Markers Initiative should not apply for funding through this initiative. Funding requests to support use of biosamples from these resources will be considered by the Foundation on a case-by-case basis. Please email resources@michaeljfox.org for more information.
Target Advancement Awards support target validation approaches and biology research on novel targets and possible convergence around established PD-relevant genetic and pathological pathways such as alpha-synuclein, GBA1, LRRK2 and Parkin/Pink1. Please note that MJFF has made significant investments in these high-priority targets and proposals to continue investigating in these areas will be considered against the existing MJFF portfolio.
This webinar provides an overview of our Foundation's funding strategy, open funding opportunities,
and the application and review processes.
12- to 18-month grants
Up to $150,000
For more information, visit the Administrative Guidelines page.
Download RFA and application template.
Log in or create account in the grant application portal.
Submit your completed application.
Please fill out the form to download the RFA and Application Template
Our Promise | Our Impact | Fox Trial Finder | Fox Shop | FAQs | Careers | Leadership & Staff | Contact Us | Español
Grand Central Station, P.O. Box 4777, New York, NY 10163-4777. Tel: 1-800-708-7644
Privacy Policy | Terms & Conditions | Site Map